Effect of gelonin immunoconjugate with monoclonal antibody MSN-1 to endometrial adenocarcinoma on antigen-producing tumor cells in vivo

Yoshibumi Kaneta, Katsumi Tsukazaki, Kaneyuki Kubushiro, Rui Aoki, Motoko Sakayori, Masakazu Ueda, Shiro Nozawa

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Missile therapy, which destroys cancer cells specifically, has been advocated as an effective modality for the treatment of carcinoma. We have developed an immunoconjugate consisting of the monoclonal antibody MSN-1 (IgM), which reacts strongly with endometrial adenocarcinomas, combined with a plant hemitoxin named gelonin via a disulfide bond using N-succinimidyl-3-(2-pyridyldithio)propionate and 2-iminothiolane, and examined its selective cytotoxicity in athymic mice. The reductions in resected weights of target tumor cells, at the local site of MSN-1-gelonin immunoconjugate treatment, were 96% with local administration and 75% with caudal vein administration, as compared with the untreated group. There was no weight loss in treated mice. Our results suggest that this MSN-1-gelonin immunoconjugate has potential clinical applications in the treatment of endometrial adenocarcinomas.

Original languageEnglish
Pages (from-to)583-588
Number of pages6
JournalJapanese Journal of Cancer Research
Volume89
Issue number5
Publication statusPublished - 1998 May

Fingerprint

Immunoconjugates
Neoplasm Antigens
Adenocarcinoma
Monoclonal Antibodies
Tumor Burden
Nude Mice
Disulfides
Immunoglobulin M
Weight Loss
Veins
Carcinoma
Gelonium multiflorum GEL protein
Neoplasms
Therapeutics

Keywords

  • Endometrial adenocarcinoma
  • Gelonin
  • In vivo
  • Missile therapy
  • MSN-1

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kaneta, Y., Tsukazaki, K., Kubushiro, K., Aoki, R., Sakayori, M., Ueda, M., & Nozawa, S. (1998). Effect of gelonin immunoconjugate with monoclonal antibody MSN-1 to endometrial adenocarcinoma on antigen-producing tumor cells in vivo. Japanese Journal of Cancer Research, 89(5), 583-588.

Effect of gelonin immunoconjugate with monoclonal antibody MSN-1 to endometrial adenocarcinoma on antigen-producing tumor cells in vivo. / Kaneta, Yoshibumi; Tsukazaki, Katsumi; Kubushiro, Kaneyuki; Aoki, Rui; Sakayori, Motoko; Ueda, Masakazu; Nozawa, Shiro.

In: Japanese Journal of Cancer Research, Vol. 89, No. 5, 05.1998, p. 583-588.

Research output: Contribution to journalArticle

Kaneta, Y, Tsukazaki, K, Kubushiro, K, Aoki, R, Sakayori, M, Ueda, M & Nozawa, S 1998, 'Effect of gelonin immunoconjugate with monoclonal antibody MSN-1 to endometrial adenocarcinoma on antigen-producing tumor cells in vivo', Japanese Journal of Cancer Research, vol. 89, no. 5, pp. 583-588.
Kaneta, Yoshibumi ; Tsukazaki, Katsumi ; Kubushiro, Kaneyuki ; Aoki, Rui ; Sakayori, Motoko ; Ueda, Masakazu ; Nozawa, Shiro. / Effect of gelonin immunoconjugate with monoclonal antibody MSN-1 to endometrial adenocarcinoma on antigen-producing tumor cells in vivo. In: Japanese Journal of Cancer Research. 1998 ; Vol. 89, No. 5. pp. 583-588.
@article{f1b9d51419aa4ae4acd97b2ce5f9d215,
title = "Effect of gelonin immunoconjugate with monoclonal antibody MSN-1 to endometrial adenocarcinoma on antigen-producing tumor cells in vivo",
abstract = "Missile therapy, which destroys cancer cells specifically, has been advocated as an effective modality for the treatment of carcinoma. We have developed an immunoconjugate consisting of the monoclonal antibody MSN-1 (IgM), which reacts strongly with endometrial adenocarcinomas, combined with a plant hemitoxin named gelonin via a disulfide bond using N-succinimidyl-3-(2-pyridyldithio)propionate and 2-iminothiolane, and examined its selective cytotoxicity in athymic mice. The reductions in resected weights of target tumor cells, at the local site of MSN-1-gelonin immunoconjugate treatment, were 96{\%} with local administration and 75{\%} with caudal vein administration, as compared with the untreated group. There was no weight loss in treated mice. Our results suggest that this MSN-1-gelonin immunoconjugate has potential clinical applications in the treatment of endometrial adenocarcinomas.",
keywords = "Endometrial adenocarcinoma, Gelonin, In vivo, Missile therapy, MSN-1",
author = "Yoshibumi Kaneta and Katsumi Tsukazaki and Kaneyuki Kubushiro and Rui Aoki and Motoko Sakayori and Masakazu Ueda and Shiro Nozawa",
year = "1998",
month = "5",
language = "English",
volume = "89",
pages = "583--588",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Effect of gelonin immunoconjugate with monoclonal antibody MSN-1 to endometrial adenocarcinoma on antigen-producing tumor cells in vivo

AU - Kaneta, Yoshibumi

AU - Tsukazaki, Katsumi

AU - Kubushiro, Kaneyuki

AU - Aoki, Rui

AU - Sakayori, Motoko

AU - Ueda, Masakazu

AU - Nozawa, Shiro

PY - 1998/5

Y1 - 1998/5

N2 - Missile therapy, which destroys cancer cells specifically, has been advocated as an effective modality for the treatment of carcinoma. We have developed an immunoconjugate consisting of the monoclonal antibody MSN-1 (IgM), which reacts strongly with endometrial adenocarcinomas, combined with a plant hemitoxin named gelonin via a disulfide bond using N-succinimidyl-3-(2-pyridyldithio)propionate and 2-iminothiolane, and examined its selective cytotoxicity in athymic mice. The reductions in resected weights of target tumor cells, at the local site of MSN-1-gelonin immunoconjugate treatment, were 96% with local administration and 75% with caudal vein administration, as compared with the untreated group. There was no weight loss in treated mice. Our results suggest that this MSN-1-gelonin immunoconjugate has potential clinical applications in the treatment of endometrial adenocarcinomas.

AB - Missile therapy, which destroys cancer cells specifically, has been advocated as an effective modality for the treatment of carcinoma. We have developed an immunoconjugate consisting of the monoclonal antibody MSN-1 (IgM), which reacts strongly with endometrial adenocarcinomas, combined with a plant hemitoxin named gelonin via a disulfide bond using N-succinimidyl-3-(2-pyridyldithio)propionate and 2-iminothiolane, and examined its selective cytotoxicity in athymic mice. The reductions in resected weights of target tumor cells, at the local site of MSN-1-gelonin immunoconjugate treatment, were 96% with local administration and 75% with caudal vein administration, as compared with the untreated group. There was no weight loss in treated mice. Our results suggest that this MSN-1-gelonin immunoconjugate has potential clinical applications in the treatment of endometrial adenocarcinomas.

KW - Endometrial adenocarcinoma

KW - Gelonin

KW - In vivo

KW - Missile therapy

KW - MSN-1

UR - http://www.scopus.com/inward/record.url?scp=0031813193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031813193&partnerID=8YFLogxK

M3 - Article

VL - 89

SP - 583

EP - 588

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 5

ER -